Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
Vistisen D, Carstensen B, Elisabetta P, Lanzinger S, Tan EC, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Núñez J, Ha KH, Halvorsen S, Langslet G, Karasik A, Nyström T, Niskanen L, Guleria S, Klement R, Carrasco M, Foersch J, Shay C, Koeneman L, Hoti F, Farsani SF, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K; EMPRISE EU; East Asia Study Group. Vistisen D, et al. Among authors: hoti f. Cardiovasc Diabetol. 2023 Aug 31;22(1):233. doi: 10.1186/s12933-023-01963-9. Cardiovasc Diabetol. 2023. PMID: 37653496 Free PMC article.
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Karasik A, Lanzinger S, Chia-Hui Tan E, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Ha KH, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K, Nyström T, Niskanen L, Linnemann Jensen M, Hoti F, Klement R, Déruaz-Luyet A, Kyaw MH, Koeneman L, Vistisen D, Carstensen B, Halvorsen S, Langslet G, Fazeli Farsani S, Patorno E, Núñez J; EMPRISE Europe and Asia Study Group. Karasik A, et al. Among authors: hoti f. Diabetes Metab. 2023 Mar;49(2):101418. doi: 10.1016/j.diabet.2022.101418. Epub 2023 Jan 3. Diabetes Metab. 2023. PMID: 36608816 Free article.
Metagenes associated with survival in non-small cell lung cancer.
Urgard E, Vooder T, Võsa U, Välk K, Liu M, Luo C, Hoti F, Roosipuu R, Annilo T, Laine J, Frenz CM, Zhang L, Metspalu A. Urgard E, et al. Among authors: hoti f. Cancer Inform. 2011;10:175-83. doi: 10.4137/CIN.S7135. Epub 2011 Jun 2. Cancer Inform. 2011. PMID: 21695068 Free PMC article.
Risk of cardiovascular events after an exacerbation of chronic obstructive pulmonary disease: results from the EXACOS-CV cohort study using the PHARMO Data Network in the Netherlands.
Swart KMA, Baak BN, Lemmens L, Penning-van Beest FJA, Bengtsson C, Lobier M, Hoti F, Vojinovic D, van Burk L, Rhodes K, Garbe E, Herings RMC, Nordon C, Simons SO. Swart KMA, et al. Among authors: hoti f. Respir Res. 2023 Nov 21;24(1):293. doi: 10.1186/s12931-023-02601-4. Respir Res. 2023. PMID: 37990197 Free PMC article.
Relationship of the Behavior of Older Participants with Body Composition Change: Results of the Second Wave of the Cognition of Older People, Education, Recreational Activities, Nutrition, Comorbidities, and Functional Capacity Studies (COPERNICUS).
Kujawska A, López Sánchez GF, Hoti F, Kujawski S, Zalewski P, Kędziora-Kornatowska K. Kujawska A, et al. Among authors: hoti f. Nutrients. 2023 Apr 11;15(8):1834. doi: 10.3390/nu15081834. Nutrients. 2023. PMID: 37111053 Free PMC article.
Prenatal exposure to pregabalin, birth outcomes and neurodevelopment - a population-based cohort study in four Nordic countries.
Dudukina E, Szépligeti SK, Karlsson P, Asomaning K, Daltveit AK, Hakkarainen K, Hoti F, Kieler H, Lunde A, Odsbu I, Rantanen M, Reutfors J, Saarelainen L, Ehrenstein V, Toft G. Dudukina E, et al. Among authors: hoti f. Drug Saf. 2023 Jul;46(7):661-675. doi: 10.1007/s40264-023-01307-2. Epub 2023 Apr 26. Drug Saf. 2023. PMID: 37099261 Free PMC article.
Validation of safety outcomes in routinely collected data: Lessons learned from a multinational postapproval safety study.
Arena PJ, Huang K, Löfling L, Bahmanyar S, Mo J, Schachterle SE, Nunes AP, Smits E, Juuti R, Hoti F, Korhonen P, Adelborg K, Sundbøll J, Rasmussen TR, Løkke A, Ehrenstein V. Arena PJ, et al. Among authors: hoti f. Pharmacoepidemiol Drug Saf. 2023 May;32(5):592-596. doi: 10.1002/pds.5582. Epub 2022 Dec 29. Pharmacoepidemiol Drug Saf. 2023. PMID: 36495188 No abstract available.
Management of COVID-19 Cases in Kosova.
Ahmeti S, Keske Ş, Namani-Avdiu S, Ajazaj-Berisha L, Vishaj A, Sadik I, Alimusaj M, Hoti F, Ahmeti H, Sait B, Çakar N, Ergönül Ö. Ahmeti S, et al. Among authors: hoti f. Infect Dis Clin Microbiol. 2022 Jun 13;4(2):144-147. doi: 10.36519/idcm.2022.125. eCollection 2022 Jun. Infect Dis Clin Microbiol. 2022. PMID: 38633341 Free PMC article. No abstract available.
Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data.
Khunti K, Kosiborod M, Kim DJ, Kohsaka S, Lam CSP, Goh SY, Chiang CE, Shaw JE, Cavender MA, Tangri N, Franch-Nadal J, Holl RW, Jørgensen ME, Norhammar A, Eriksson JG, Zaccardi F, Karasik A, Magliano DJ, Thuresson M, Chen H, Wittbrodt E, Bodegård J, Surmont F, Fenici P; CVD-REAL Investigators and Study Group. Khunti K, et al. Cardiovasc Diabetol. 2021 Jul 31;20(1):159. doi: 10.1186/s12933-021-01345-z. Cardiovasc Diabetol. 2021. PMID: 34332558 Free PMC article.
59 results